China approves Galderma Relfydess: what it means for Galderma stock
Published on 10/24/2026 at 10:27 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSChina approval and market context
- Galderma announced Chinese approval for Relfydess on October 23, 2026.
- Galderma stock trades in weekend trading at Lang & Schwarz at EUR 207.85 at 10:26 a.m. CEST on October 24, 2026.
- The next Xetra session is scheduled for October 26, 2026.
China approved Galderma’s Relfydess for frown lines on October 23, 2026, according to a Galderma press release. The Chinese National Medical Products Administration authorized the ready-to-use liquid neuromodulator for the temporary improvement of moderate-to-severe glabellar lines in adults.
Market context: Market report SMI.
The week in figures
At 10:26 a.m. CEST on October 24, 2026, Galderma stock traded in weekend trading at Lang & Schwarz at EUR 207.85. The quotation is a euro indication while Xetra and the primary exchanges are closed.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Galderma stock.
Chronology of the week
On October 23, 2026, Galderma announced that the Chinese NMPA had approved Relfydess. The company said the approval follows authorizations and launches in more than 35 markets worldwide. Galderma expects to commercially launch Relfydess in China in the second half of 2027, subject to applicable conditions, according to the company release.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. Galderma’s announcement identifies the expected Chinese commercial launch period for Relfydess as the second half of 2027.
